INTRODUCTION
Ovarian hyperstimulation syndrome (OHSS) is one of the most serious iatrogenic complications during controlled ovarian hyperstimulation (COH) (1) (2) (3) (4) (5) . In its severe form, with a reported prevalence of 0.5-5% of all OHSS cases (2, 3, 5) , it is a potentially lifethreatening condition (1) (2) (3) .
Pathogenesis of OHSS is likely to be multifactorial (4) . Recently, the involvement of certain vasoactive mediators (2, 4, 5) and FSH receptor gene mutations 1 The paper was presented in part at the European Human Genetics Conference 2004 (ESHG), in Munich, Germany at June 12, 2004. 2 Department of Obstetrics and Gynaecology, Division of Medical Genetics, University Medical Centre, SI-1000 Ljubljana Slovenia. 3 To whom correspondence should be addressed at Department of Obstetrics and Gynaecology, Division of Medical Genetics, University Medical Centre, SI-1000, Ljubljana, Slovenia; e-mail: ksenija.gersak@mf.uni-lj.si.
(5) has been suggested. Despite numerous investigations, pathogenetic background of the syndrome has not been completely elucidated. Therefore, effective prognostic criteria for OHSS are still lacking. Our research was based on the observation that women with biochemical marker-based diagnosis of polycystic ovary syndrome (BM-PCOS) (1, 4, 6) as well as those with ultrasonic evidence of polycystic ovaries (US-PCOS), are at higher risk of OHSS. Moreover, the clinical and biochemical picture of OHSS are similar in both groups of patients (7) .
Women with BM-PCOS are mainly characterized by disturbances in androgen biosynthesis (8) (9) (10) (11) (12) (13) (14) (15) (16) , before as well as during COH. On the other hand, women with US-PCOS have normal androgen status before COH; however, their androgen biochemical picture is changed during COH (7) .
Probably, androgen pathogenetic mechanism of OHSS could be related to a certain genetic predisposition.
We focused on investigating a possible association of the (TTTTA) n microsatellite polymorphism in the promoter of the CYP11A gene with OHSS during COH. Namely, the CYP11A gene product, cholesterol side chain cleavage enzyme, catalyzes the first, rate-limiting step in steroidogenesis (17) , and the gene itself is one of the candidate genes for hyperandrogenemia (8) (9) (10) (11) (12) (13) (14) (15) (16) . Furthermore, the (TTTTA) n microsatellite polymorphism might influence the expression of the CYP11A gene and consequently cause abnormalities in steroidogenesis and androgen production.
The study was approved by the National Medical Ethics Committee of the Republic of Slovenia (No. 97/05/01).
MATERIALS AND METHODS
A total of 116 patients undergoing COH at the Department of Obstetrics and Gynecology, University Medical Centre Ljubljana, Slovenia, were enrolled in the study between 1996 and 2002. Fifty-eight were at high risk of OHSS and were included in the study group, whereas the control group consisted of 58 patients without signs of risks of OHSS. The criteria used to identify cycles at risk of OHSS were those described by Tomazevic et al. (18) .
In all women, the diagnosis of PCOS was excluded according to the criteria defined by Homburg (19), but they had polycystic ovaries on ultrasound before beginning COH, and were treated for tubal infertility factor or male infertility.
Genomic DNA was isolated from peripheral blood leukocytes using the standard method (20) . A DNA fragment containing the (TTTTA) n microsatellite marker was amplified from genomic DNA by polymerase chain reaction (PCR). The primers used were: Forward primer GGT-GAAACTGTGCCATTGC and reverse primer GTTTGGGGGAAATGAGGGGC (9, 12, 14) . The reaction mixture had a total volume of 15 µl and contained 90 ng of genomic DNA and 1.5 units of Taq DNA polymerase in Storage Buffer A (Promega, UK), whereas the concentrations of other components were the following: 0.33 µM of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl 2 and 1× reaction buffer (Promega, UK). The reaction conditions were as follows: Initial denaturation step of 5 min at 94
• C, 30 cycles of 1 min of denaturation at 94
• C, 1 min of annealing at 61
• C, 1 min of extension at 72
• C and final extension of 10 min at 72
• C. To separate PCR products of different sizes, electrophoresis on Spreadex TM EL 800 Mini gels (Elchrom Scientific, Switzerland) at 55
• C was performed, according to the manufacturer's recommendations. The gel was stained with Syber Gold (Pharmacia, UK) to permit visualization of DNA bands on ultraviolet irradiation (Fig. 1) . The size of separated DNA fragments was determined according to the M3 marker (Elchrom Scientific, Switzerland) using the Wincam Image Analysis computer program (Cybertech, Ontario). Then, the number of TTTTA repeats in the promoter of the CYP11A gene was calculated from the size of the PCR products in relation to a series of standards that were obtained by direct sequencing of four PCR products, different in size, using automatic DNA sequencer ABI PRISM 310 (PE Applied Biosystems, USA).
Chi-square test was used to compare the allele and genotype distributions between the study and the control group of patients, using SPSS for Windows (version 11.0; SPSS, Illinois). A p-value of <0.05 was considered statistically significant.
RESULTS
All patients were typed for the CYP11A (TTTTA) n microsatellite allelic variants. In both groups, four different alleles were identified: An allele with four, an allele with six, an allele with Note. The CYP11A genotypes are designated as the number of TTTTA repeats in both CYP11A alleles.
eight and an allele with nine TTTTA repeats. The observed allele frequencies in the study group were 0.51, 0.26, 0.14, 0.09, and in the control group 0.49, 0.29, 0.11 and 0.10, for alleles with four, six, eight and nine TTTTA repeats. The difference in the allele distribution between the two groups was not statistically significant (p = 0.888).
To avoid multiple allele comparisons among infrequent alleles, we classified the patients according to the presence or absence of the most common allele, the four-repeat-unit allele. Patients with at least one copy of the four-repeat-unit allele were classified as having 4+ genotype, and patients without the fourrepeat-unit allele as having 4− genotype. Distributions of 4+ and 4− genotypes in the study and in the control group were identical; in both groups, 44 (75.9%) patients had 4+ genotype and 14 (24.1%) had 4− genotype.
A detailed distribution of the CYP11A genotypes in the study and control group of patients is shown in Table I .
DISCUSSION
Prevention of OHSS represents an important task in assisted reproduction, but no reliable tests have been available to predict the patients at risk of OHSS before beginning COH. The aim of the present study was to establish a possible genetic criterion for identification of patients at high risk of OHSS and thus to optimize ovulation induction therapy for each individual patient.
Our study was based on the observations that women with BM-PCOS (1,4,6) as well as those with US-PCOS, are at higher risk of OHSS, and that the clinical and biochemical picture of OHSS are similar in the two groups of patients, with disturbances in androgen status during COH as one of the typical characteristics, despite differences in androgen status before being treated in COH (7) .
Possibly, androgen pathogenetic mechanism of OHSS could be related to a certain genetic predisposition. We focused on investigating a possible association of the (TTTTA) n microsatellite polymorphism in the promoter of the CYP11A gene with the development of OHSS during COH. Namely, the CYP11A gene participates in the first, rate-limiting step in steroidogenesis (17) and it is one of the most promising candidate genes for abnormalities in androgen biosynthesis (8) (9) (10) (11) (12) (13) (14) (15) (16) . Furthermore, the (TTTTA) n microsatellite polymorphism could regulate transcriptional activity of the CYP11A gene, as regulation of a gene transcription has been described as one of the major possible functions of variable number of tandem repeat (VNTR) polymorphisms, with a classical example of VNTR polymorphism in the insulin gene (21) .
In the present study, four different CYP11A (TTTTA) n alleles were identified within either group of patients: the four-, the six-, the eight-and the nine-repeat-unit allele, confirming the observations already reported (9, 12, 14) . The observed allele frequencies were comparable to those obtained with CYP11A genotyping in previous studies (9, 12, 14) .
Moreover, we compared the CYP11A (TTTTA) n allele distribution between both groups of patients. The difference was not statistically significant, indicating that none of the allelic variants was associated with an increased risk of OHSS.
In order to reduce multiple allele comparisons, the patients in both groups were further divided into those with the presence and those with the absence of the four-repeat-unit allele (having 4+ or 4− genotype, respectively). The genotype distribution analysis clearly shows that 4+ and 4− genotypes were identically distributed in the study and in the control group of patients, suggesting none of the genotype was associated with the pathogenesis of OHSS.
However, a relatively small number of patients at high risk of OHSS could influence the power to detect any association. More patients should be tested to avoid a statistical type 2 error. But the number of patients is limited with the incidence of OHSS, which is less than 1% of all stimulated cycles recorded from the register of the Department of Obstetrics and Gynaecology Ljubljana (approximately 1000 cycles per year) (22) .
Another consideration in this respect is that dividing genotypes in 4+ and 4− genotype groups could not be sufficiently precise, since transcriptional activity of a gene does not necessarily correlate proportionally with a number of microsatellite repeats. For instance, the expression studies of the (TTTTA) n microsatellite polymorphism in the apolipoprotein(a) gene have shown a five-fold higher level of transcriptional activity in constructs with eight copies of TTTTA repeats compared to those with nine copies (12) .
To our knowledge, an association of the CYP11A allelic variants with OHSS has not yet been investigated, but some results on CYP11A genotyping in association with certain steroidogenic pathway disturbances have already been published. In Spanish hirsute women, no association between whichever CYP11A allelic or genotype variant and hirsutism was found (14) . On the other hand, an association between PCOS and 4− genotype has been reported for English (9) and Greek (12) PCOS patients.
According to the results of molecular genetic analysis in our study, an association between the (TTTTA) n microsatellite polymorphism in the CYP11A gene and the pathogenesis of OHSS could not be confirmed. In future, from a genetic point of view, further candidate genes should be investigated in order to find proper genetic prognostic criteria for prevention of severe OHSS. As the pathogenesis of OHSS seems to be multifactorial (4), it would be particularly appropriate to test a simultaneous influence of different gene candidate markers on development of OHSS.
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